Stem Cell Innovations produces human pluripotent stem cells

By Lisa Kerner

Erie, Pa., March 29 - Stem Cell Innovations, Inc. said it has produced multiple lines of human pluripotent stem cells, which can develop into most, if not all, of the tissues of an organism.

Stem Cell Innovations chief executive officer James H. Kelly will present data in support of the company's claim at the Keystone Symposium on Stem Cells in Vancouver, B.C.

Since pluripotent cells are derived from fetal tissue, not early embryos, they are eligible for use in laboratories funded by the National Institutes of Health, according to a company news release.

The two types of mammalian stem cells shown to be truly pluripotent are the embryonic stem (ES) cells cultured from very early embryos, and embryonic germ (EG) cells developed from fetal gonadal tissue, the company said.

EG cells have been patented and licensed exclusively to Amphioxus Cell Technologies, Inc., a wholly owned subsidiary of the Stem Cell Innovations. These cells are difficult to isolate and grow, while the widespread use of ES cells has been slowed by ethical issues and government funding limitations.

Kelly's presentation will explain how Stem Cell Innovations' overcame problems inherent in the production of EG cells.

Specifically, he will address how his company's cell lines maintain their undifferentiated state and normal chromosome complement, how Stem Cell Innovations produces its cell lines without feeder layers and how it creates banks of cells for patient matching.

Stem Cell Innovations is a cell biology company based in Scotch Plains, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.